date:Mar 21, 2013
this week.
As agreed, BGI-Shenzhen paid $3.15 in cash for each Complete Genomics share, an 18 percent premium to the stock's $2.67-a-share closing price on Sept 14, shortly before the deal was announced.
BGI-Shenzhen is continuing to operate Complete Genomics, whose technology can sequence human DNA for research, as a wholly owned subsidiary, allowing the Chinese company to offer a broad array of genomic research technology across a variety of platforms, it said.
Clifford Reid, a co-founder o